Group FY19 results are broadly in line with the April trading update; overall top-line increased by 7.0% and trading profit increased 10.7%. End markets within Industrial remain tough and we believe this will continue to weigh on the division. Healthcare appears to have had somewhat of an H2 recovery and it is encouraging to see the Systagenix deal progressing well. We do, however, believe upside is limited at this stage at an FY20 adjusted P/E of 20.5x, given the headwinds within Industrial
21 May 2019
FY19 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY19 results
- Published:
21 May 2019 -
Author:
Michael White -
Pages:
2
Group FY19 results are broadly in line with the April trading update; overall top-line increased by 7.0% and trading profit increased 10.7%. End markets within Industrial remain tough and we believe this will continue to weigh on the division. Healthcare appears to have had somewhat of an H2 recovery and it is encouraging to see the Systagenix deal progressing well. We do, however, believe upside is limited at this stage at an FY20 adjusted P/E of 20.5x, given the headwinds within Industrial